TY - JOUR
T1 - Exploration of residual disease in stem cell products from mantle cell lymphoma using next-generation sequencing
AU - Elkjær, Lea Amalia Lind
AU - Cédile, Oriane
AU - Hansen, Marcus Høy
AU - Nielsen, Christian
AU - Møller, Michael Boe
AU - Abildgaard, Niels
AU - Haaber, Jacob
AU - Nyvold, Charlotte Guldborg
N1 - Funding Information:
The project received funding from the Danish Medical Association, the Danish Cancer Society, the Harboe Foundation, the OUH Free Research Fund, the Danish Lymphoma Group and the Torben and Alice Frimodt's foundation. We thank Dennis Lund Hansen for his expertise in survival analysis (Department of Haematology, OUH), Vickie Svane Kristensen (Research Unit for Haematology, OUH) for language assistance and Nina Friis Jensen (Department of Pathology, OUH) for excellent technical assistance.
Funding Information:
The project received funding from the Danish Medical Association, the Danish Cancer Society, the Harboe Foundation, the OUH Free Research Fund, the Danish Lymphoma Group and the Torben and Alice Frimodt's foundation . We thank Dennis Lund Hansen for his expertise in survival analysis (Department of Haematology, OUH), Vickie Svane Kristensen (Research Unit for Haematology, OUH) for language assistance and Nina Friis Jensen (Department of Pathology, OUH) for excellent technical assistance.
Publisher Copyright:
© 2022
PY - 2022/1
Y1 - 2022/1
N2 - High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has become a treatment option for fit patients with mantle cell lymphoma (MCL). However, these patients often relapse within few years, potentially caused by contaminating lymphoma cells within the reinfused stem cell product (SCP). Studies have shown that measurable residual disease, also termed minimal residual disease (MRD), following ASCT predicts shorter survival. Using next-generation sequencing, we explore whether the diagnostic MCL clonotype is present within the infused SCP. MRD was detected in 4/17 of the SCPs, ranging 4–568 clonal cells/100,000 cells. With a median survival of 17 months, 3/4 of patients with MRD+ graft succumbed from MCL relapse versus 2/13 in the MRD– fraction. Patients receiving MRD+ grafts had increased risk of mortality, and thus screening of SCPs may be important for clinical decision-making.
AB - High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has become a treatment option for fit patients with mantle cell lymphoma (MCL). However, these patients often relapse within few years, potentially caused by contaminating lymphoma cells within the reinfused stem cell product (SCP). Studies have shown that measurable residual disease, also termed minimal residual disease (MRD), following ASCT predicts shorter survival. Using next-generation sequencing, we explore whether the diagnostic MCL clonotype is present within the infused SCP. MRD was detected in 4/17 of the SCPs, ranging 4–568 clonal cells/100,000 cells. With a median survival of 17 months, 3/4 of patients with MRD+ graft succumbed from MCL relapse versus 2/13 in the MRD– fraction. Patients receiving MRD+ grafts had increased risk of mortality, and thus screening of SCPs may be important for clinical decision-making.
KW - Autologous stem cell transplantation
KW - Mantle cell lymphoma
KW - Measurable residual disease
KW - Minimal residual disease
KW - Relapse
U2 - 10.1016/j.lrr.2022.100341
DO - 10.1016/j.lrr.2022.100341
M3 - Journal article
C2 - 36039182
AN - SCOPUS:85135926197
SN - 2213-0489
VL - 18
JO - Leukemia Research Reports
JF - Leukemia Research Reports
M1 - 100341
ER -